NEUROCRINE BIOSCIENCES Trademark

Trademark Overview


On Monday, August 16, 2021, a trademark application was filed for NEUROCRINE BIOSCIENCES with the United States Patent and Trademark Office. The USPTO has given the NEUROCRINE BIOSCIENCES trademark a serial number of 90884742. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Monday, August 5, 2024. This trademark is owned by Neurocrine Biosciences, Inc.. The NEUROCRINE BIOSCIENCES trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Pharmaceutical preparations for human use for treatment of Huntington's Disease, chorea associated with Huntington's Disease, schizophrenia, adjunctive treatment of schizophrenia, cognitive impairment associated with schizophrenia, epilepsy, epileptic encephalopathy with continuous spike-and-wave during sleep, SCN8A-related epilepsy with encephalopathy, focal onset seizures, Parkinson's Disease, adjunctive treatment of Parkinson's Disease, Major Depressive Disorder, anhedonia in Major Depressive Disorder, inadequate response to treatment in Major Depressive Disorder, dyskinetic cerebral palsy, and neuro-immunological and neuro-endocrinological diseases, disorders, and conditions; Pharmaceutical preparations for the diagnosis, prevention and treatment of hormonal and genetic diseases, disorders and conditions; Pharmaceutical preparations for the diagnosis and prevention of psychiatric, neurological, central nervous system, and movement diseases, disorders and conditions; pharmaceutical ...

providing medical information in the field of hormonal and genetic diseases, disorders and conditions; on-line information services, namely, providing medical information in the field of hormonal and genetic diseases, disorders and conditions

pharmaceutical drug development services in the field of hormonal and genetic diseases, disorders and conditions
neurocrine biosciences

General Information


Serial Number90884742
Word MarkNEUROCRINE BIOSCIENCES
Filing DateMonday, August 16, 2021
Status732 - THIRD EXTENSION - GRANTED
Status DateMonday, August 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, December 13, 2022

Trademark Statements


Description of MarkThe mark consists of a stylized circular spiral design with the top spiral piece in aqua blue, the right one starting is aqua blue on the left and fading to pink on the right and the left one in pink with "NEUROCRINE" above "BIOSCIENCES" in block lettering to the right where NEUROCRINE is fading from a darker shade of aqua blue on the left to a lighter shade on the right and BIOSCIENCES in gray.
Goods and ServicesPharmaceutical preparations for human use for treatment of Huntington's Disease, chorea associated with Huntington's Disease, schizophrenia, adjunctive treatment of schizophrenia, cognitive impairment associated with schizophrenia, epilepsy, epileptic encephalopathy with continuous spike-and-wave during sleep, SCN8A-related epilepsy with encephalopathy, focal onset seizures, Parkinson's Disease, adjunctive treatment of Parkinson's Disease, Major Depressive Disorder, anhedonia in Major Depressive Disorder, inadequate response to treatment in Major Depressive Disorder, dyskinetic cerebral palsy, and neuro-immunological and neuro-endocrinological diseases, disorders, and conditions; Pharmaceutical preparations for the diagnosis, prevention and treatment of hormonal and genetic diseases, disorders and conditions; Pharmaceutical preparations for the diagnosis and prevention of psychiatric, neurological, central nervous system, and movement diseases, disorders and conditions; pharmaceutical preparations for human use for diagnosis, prevention and treatment of diseases and disorders by gene therapy; pharmaceuticals for human use for the treatment of rare and orphan diseases, disorders and conditions; pharmaceutical preparations for the treatment of congenital adrenal hyperplasia
Indication of Colors claimedThe color(s) pink, gray and aqua blue is/are claimed as a feature of the mark.
Goods and Servicesproviding medical information in the field of hormonal and genetic diseases, disorders and conditions; on-line information services, namely, providing medical information in the field of hormonal and genetic diseases, disorders and conditions
NOT AVAILABLE"BIOSCIENCES"
Goods and Servicespharmaceutical drug development services in the field of hormonal and genetic diseases, disorders and conditions

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, October 5, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, October 5, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, October 5, 2021
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNeurocrine Biosciences, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130

Party NameNeurocrine Biosciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130

Trademark Events


Event DateEvent Description
Tuesday, May 3, 2022ASSIGNED TO EXAMINER
Thursday, August 19, 2021NEW APPLICATION ENTERED
Tuesday, October 5, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, October 6, 2021NOTICE OF DESIGN SEARCH CODE E-MAILED
Thursday, May 5, 2022EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Thursday, May 5, 2022COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
Thursday, May 5, 2022EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Thursday, May 5, 2022NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Friday, November 4, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, November 4, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, November 5, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, November 5, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 23, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 13, 2022PUBLISHED FOR OPPOSITION
Tuesday, December 13, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 7, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, July 14, 2023SOU TEAS EXTENSION RECEIVED
Friday, July 14, 2023SOU EXTENSION 1 FILED
Friday, July 14, 2023SOU EXTENSION 1 GRANTED
Tuesday, July 18, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 9, 2023TEAS REQUEST TO DIVIDE RECEIVED
Monday, October 9, 2023DIVISIONAL REQUEST RECEIVED
Monday, October 9, 2023SOU EXTENSION 2 FILED
Monday, October 9, 2023SOU TEAS EXTENSION RECEIVED
Friday, October 20, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, October 24, 2023DIVISIONAL PROCESSING COMPLETE
Tuesday, October 24, 2023SOU EXTENSION 2 GRANTED
Wednesday, October 25, 2023CORRECTED NOA E-MAILED
Wednesday, October 25, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 5, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 5, 2024SOU EXTENSION 3 FILED
Monday, August 5, 2024SOU TEAS EXTENSION RECEIVED
Monday, August 5, 2024SOU EXTENSION 3 GRANTED